Axon Enterpri

Axon’s moat is multi-layered. Switching costs are very high because Evidence.com holds years of sensitive digital evidence, case links, and workflows across police, prosecutors and courts; migrating at scale is risky, expensive and politically sensitive. Net revenue retention of 125 percent evidences cross-sell and upsell within the installed base.

Network effects arise as more agencies, prosecutors and partners exchange evidence and data across the platform. Brand and regulatory trust are meaningful in a market where reliability, security and FedRAMP compliance matter; Axon serves over 17,000 US state and local agencies and is deployed in more than 85 countries.

Intangible assets include large IP estates and proprietary datasets from millions of hours of video that improve AI features like transcription, summarization and search. Efficient scale exists in categories such as TASER energy devices and cloud evidence where few players can match the breadth of the integrated stack.

Moat erosion risks include aggressive competition from Motorola Solutions across cameras, evidence, real-time ops and NG911, and potential regulatory constraints on ALPR or AI.

Pricing power is solid and improving as mix tilts to software and premium bundles.

Evidence.com and adjacent applications are a small fraction of agency budgets relative to the operational and legal risks they mitigate, allowing for periodic price and package enhancement without material churn. 2025 software and services reached roughly 40 percent of revenue, and ARR grew 35 percent year over year, indicating customers are adopting higher-value modules.

Offsetting factors are public procurement processes and budget cycles that limit mid-contract repricing, and political scrutiny that can pressure ALPR or AI-related pricing. Overall, we see room for continued ARPU expansion through AI assistants, real-time operations, and 911 integrations that increase mission-criticality per seat.

Axon combines tollbooth-like subscriptions with multi-year hardware and service bundles. The company delivered four consecutive years of greater than 30 percent annual revenue growth through 2025, carries 1.3 billion dollars ARR, and closed the year with 14.4 billion dollars of future contracted bookings.

Management’s 2026 outlook calls for 27 to 30 percent revenue growth, and a 2028 target of 6 billion dollars revenue with 28 percent adjusted EBITDA margin.

These are supported by strong bookings, premium-plan adoption and a growing product surface area across TASER, cameras, Fusus, ALPR and 911. Geographic and end-market diversification is improving with international, corrections and federal wins, though US municipal budgets remain the core exposure.

Key uncertainties are regulatory shifts and procurement timing, but the backlog, ARR and NRR create unusually high visibility.

Liquidity is robust, with 1.2 billion dollars cash and 505 million dollars in investments at December 31, 2025. Debt consists mainly of 1.75 billion dollars of senior notes due 2030 and 2033; the remaining 2027 convertible notes were fully redeemed or converted in February 2026. Free cash flow troughed in 2025 at 75 million dollars due to inventory and receivables timing, but management reiterated a long-term 60 percent free cash flow conversion of adjusted EBITDA as working capital normalizes.

The balance sheet can absorb investment cycles and M&A, but interest expense has risen and dilution from stock-based compensation has been significant. Net leverage is manageable given cash and recurring cash generation, yet we monitor cash deployment post-Carbyne and Prepared.

Reinvestment in R&D and go-to-market has compounded product breadth and bookings, which we applaud. However, 2025 capital allocation included 1.75 billion dollars of new senior notes, roughly 0.7 million shares sold via ATM, and total stock-based compensation of about 634 million dollars that materially diluted owners.

Strategic M&A has been active: Fusus in 2024, Prepared closed late 2025, and Carbyne closed in Q1 2026, extending Axon into 911 and NG911 call handling. These deals are strategically coherent and broaden the moat, but elevate integration and execution risk.

We would prefer a path to lower SBC intensity and targeted buybacks once FCF conversion returns to plan.

Axon is founder-led by Rick Smith, whose long-term vision and willingness to invest through cycles have repeatedly opened new vectors of growth, from TASER to cloud evidence to AI-first workflows. The team delivered 2025 results with adjusted EBITDA margin of 25.5 percent and set credible multi-year targets.

Management communicates with unusual clarity via detailed shareholder letters and investor materials. Areas to improve: tighten SBC, maintain rigorous post-merger integration discipline, and continue strengthening controls after past control remediation disclosures.

Overall alignment and execution quality are strong for a company of this scale and scope.